GlassScriptPhysician profile
Jonathan Mendoza
NPI 1760942742
$1,798.82
in general payments reported to CMS, 2019-2025
19 companies · $960 in 2025
The $960 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.63 · 2022: $210 · 2023: $328 · 2024: $287 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,574.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.71 | 2023-2025 | |
| Madrigal Pharmaceuticals | $288.91 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $237.09 | 2022-2023 | Opdivo |
| Intuitive Surgical, INC. | $132.01 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2023 | Ofev |
| Phathom Pharmaceuticals, INC. | $124.70 | 2024 | Voquezna |
| Elekta, INC. | $120.00 | 2025 | Leksell Gamma Knife Icon |
| Takeda Pharmaceuticals U.S.A., INC. | $105.64 | 2022-2025 | Entyvio, Eohilia, Gattex |
| Ardelyx, INC. | $69.99 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $50.56 | 2021-2025 | Xifaxan |
| Janssen Biotech, INC. | $44.09 | 2023 | Stelara |
| Redhill Biopharma INC. | $39.34 | 2023-2024 | Talicia, Aemcolo |
| Merck Sharp & Dohme LLC | $34.26 | 2022 | |
| Aimmune Therapeutics, INC. | $22.55 | 2025 | Vowst |
| Sanofi-Aventis U.S. LLC | $21.32 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $20.37 | 2025 | Korlym |
| Novo Nordisk INC | $14.86 | 2025 | Wegovy |
| Baudax Bio INC. | $13.56 | 2022 | |
| Ucb, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Mendoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.